First-in-class TREX2 inhibitors to treat psoriasis and atopic dermatitis
Problema a solucionar
Psoriasis and dermatitis are serious common skin inflammatory diseases with important and challenging unmet medical needs to date. So far, these diseases have no cure and require life-long and long-term treatments, resulting in a high burden for patients and elevated health care costs. Available treatments and most of the pharmacological therapies in development, target immune system players that over time may develop broad adverse side effects. So far, biologic agents for atopic dermatitis show relatively low efficacy. Therefore, novel therapies with improved specificity, efficacy and safety are needed.
Oportunitats de mercat
Altogether, psoriasis and dermatitis affect more than 300 million individuals worldwide requiring life-long and long-term therapies with increased specificity, efficacy and safety needs, in particular for moderate-to-severe forms of disease. This is a huge and growing market for pharmaceutical companies. The global market size for psoriasis and atopic dermatitis were about 27.1 and 10.32 billion USD in 2022, respectively, and are expected to reach 57.7 billion and 22.62 billion USD by 2032. An EP patent (EP23382389.7) covering the composition of matter and use in psoriasis of TREX2 inhibitors was submitted in April 2023.
Tecnologia
Our technology refers to the first-in-class small molecules that selectively and effectively inhibit TREX2 exonuclease and their therapeutic applications, as a non-immunosuppressive skin directed drug for psoriasis and dermatitis.
Autors
Concepció Soler Prat
Technology Readiness Level
TRL5
Què busquem?
Partners for license agreement and/other type of collaboration with industrial partners